Waking Up To REMS: Sponsors Should Test Risk Management In Phase III
Executive Summary
With Risk Evaluation and Mitigation Strategies supplanting Risk Minimization Action Plans, drug sponsors would be well served to begin preparing for negotiations over risk management plans during product development
You may also be interested in...
FDA Learns By Doing In Using REMS Powers; Guidance In “Future”
FDA decisions on whether to require a risk evaluation and mitigation strategy for a new drug will continue to be made on a case-by-case basis while the agency gains on-the-job experience in interpreting requirements of the FDA Amendments Act
FDA Learns By Doing In Using REMS Powers; Guidance In “Future”
FDA decisions on whether to require a risk evaluation and mitigation strategy for a new drug will continue to be made on a case-by-case basis while the agency gains on-the-job experience in interpreting requirements of the FDA Amendments Act
Cymbalta Fibromyalgia Approval Sets Another REMS Precedent
FDA's approval of Lilly's Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation and Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides